Secondary solid tumors after allogeneic hematopoietic SCT in Japan
Secondary solid tumors after allogeneic hematopoietic SCT in Japan
复制标题
DOI：
10.1038/bmt.2011.23
复制
发表时间：
2012-01-01
影响因子：
4.8
通讯作者：
Okamoto, S.
中科院分区：
文献类型：
--
作者：
Yokota, A.;Ozawa, S.;Okamoto, S.
为了评价日本异基因造血干细胞移植（allo-HSCT）后继发性实体瘤的发病率和危险因素，回顾性分析了1984年至2005年间接受allo-HSCT的2062例患者。28名患者在移植后的中位数为5.6年时发生了30例实体瘤。发生肿瘤的风险比年龄和性别调整的一般人群高2.16倍。allo-HSCT后10年实体瘤的累积发生率为2.4%。皮肤肿瘤、口腔肿瘤和食管肿瘤的危险性显著较高（标准偶然比分别为40.23、35.25和10.73）。尽管胃癌、结肠癌或肺癌是日本最常见的肿瘤，但未观察到增加。在多因素分析中，慢性GVHD和恶性淋巴瘤作为原发病的发生与发生实体瘤的风险较高相关。18名患者仍然存活，自诊断为实体瘤以来，他们的5年生存概率为59.7%。我们的数据表明，日本allo-HSCT受者继发性实体瘤的发病率和风险因素与西方国家报道的相当，并强调实体瘤的早期检测在改善OS方面具有关键作用。Bone Marrow Transplantation（2012）47，95-100; doi：10.1038/bmt.2011.23; 2011年2月28日在线发表
To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age-and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS. Bone Marrow Transplantation (2012) 47, 95-100; doi: 10.1038/bmt.2011.23; published online 28 February 2011